105,000 Shares in Progyny, Inc. $PGNY Acquired by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 105,000 shares of the company’s stock, valued at approximately $2,260,000. Hussman Strategic Advisors Inc. owned about 0.12% of Progyny as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. grew its holdings in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new position in Progyny during the second quarter worth about $10,525,000. Nomura Holdings Inc. acquired a new stake in Progyny in the 2nd quarter valued at about $9,368,000. Fort Washington Investment Advisors Inc. OH lifted its stake in Progyny by 33.1% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock worth $35,649,000 after purchasing an additional 412,395 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in shares of Progyny during the 2nd quarter worth approximately $4,670,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Activity at Progyny

In other news, CEO Peter Anevski bought 79,500 shares of the business’s stock in a transaction on Thursday, November 13th. The shares were bought at an average price of $24.29 per share, with a total value of $1,931,055.00. Following the completion of the transaction, the chief executive officer directly owned 680,251 shares in the company, valued at $16,523,296.79. This trade represents a 13.23% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Mark S. Livingston sold 21,303 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $25.50, for a total value of $543,226.50. Following the transaction, the chief financial officer owned 48,358 shares of the company’s stock, valued at approximately $1,233,129. This represents a 30.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 22,046 shares of company stock worth $561,691. Company insiders own 9.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PGNY shares. JPMorgan Chase & Co. set a $35.00 price target on Progyny in a research report on Wednesday, January 21st. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 1st. Canaccord Genuity Group lifted their price target on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a report on Monday, November 17th. Finally, Citizens Jmp raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a research report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $29.36.

Progyny Stock Down 2.4%

Shares of Progyny stock opened at $24.25 on Wednesday. The firm has a market cap of $2.09 billion, a PE ratio of 38.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.93. Progyny, Inc. has a 52 week low of $17.98 and a 52 week high of $28.75. The business’s fifty day simple moving average is $25.72 and its 200-day simple moving average is $23.31.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.06. The firm had revenue of $313.35 million during the quarter, compared to the consensus estimate of $299.23 million. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The company’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period last year, the company earned $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. As a group, equities analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current year.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.